TACTI-002 study expanded in lung cancer
New phase II trial in head and neck cancer announced
EOC Pharma starts new phase II study in metastatic breast cancer
Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.
After 48 Years, NCI Aims to Track Breast Cancer Recurrences
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
European Commission approves Roche s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.